Related Experiment Videos
Identification of transforming growth factor-beta1-binding protein overexpression in carmustine-resistant glioma
S A Norman1, S N Rhodes, S Treasurywala
1Neuro-Oncology Research, Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, Arizona 85013, USA.
Background:
The authors previously demonstrated the presence of cells in primary human malignant gliomas that intrinsically are resistant to carmustine (BCNU). Numerous studies have identified mechanisms of therapy resistance in these cells; however, the authors' work and that of others suggest that additional mechanisms of resistance exist.
Methods:
The authors identified a glioma cell line that lacks detectable methylguanine methyltransferase expression and does not alter its expression of glutathione-S-transferase-pi in response to BCNU chemotherapy. This cell line was used in mRNA differential display experiments to identify genes involved in what to the authors' knowledge were previously undescribed mechanisms of resistance.
Results:
The overexpression of the gene encoding the transforming growth factor latency binding protein was demonstrated in glioma cells selected for resistance to BCNU, compared with their parental unselected cells.
Conclusions:
Transforming growth factor-beta1 has pleiotropic functions in transformed and normal cells. Although activation of TGF-beta1 does not appear to be a causative factor in BCNU resistance in the current study, it may be involved in the growth of these resistant cells.
Insights
Researchers identified a new mechanism of resistance to carmustine (BCNU) chemotherapy in glioma cells. Overexpression of transforming growth factor-beta1 binding protein was observed in BCNU-resistant cells, suggesting a role in tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Primary human malignant gliomas contain cells intrinsically resistant to carmustine (BCNU).
- Existing research identifies several therapy resistance mechanisms, but suggests additional factors are involved.
- Understanding these mechanisms is crucial for improving glioma treatment outcomes.
Purpose of the Study:
- To identify novel mechanisms of resistance to carmustine (BCNU) in glioma cells.
- To investigate the role of specific gene expression changes in BCNU resistance.
- To explore potential therapeutic targets for overcoming treatment resistance.
Main Methods:
- Utilized a BCNU-resistant glioma cell line with no detectable methylguanine methyltransferase expression.
- Employed mRNA differential display to identify genes associated with BCNU resistance.
- Compared gene expression profiles between BCNU-resistant and parental glioma cells.
Main Results:
- Demonstrated overexpression of the gene encoding transforming growth factor-beta1 latency binding protein in BCNU-selected glioma cells.
- Identified this gene as potentially involved in previously undescribed resistance mechanisms.
- Found no evidence that transforming growth factor-beta1 activation directly causes BCNU resistance in this model.
Conclusions:
- Transforming growth factor-beta1 latency binding protein is overexpressed in BCNU-resistant glioma cells.
- While not directly causing resistance, TGF-beta1 may contribute to the proliferation of these resistant cells.
- Further research is warranted to elucidate the precise role of TGF-beta1 in glioma progression and resistance.